Agomab Therapeutics Secures $89 Million to Advance Fibrotic Disease Treatments
核心洞察
Agomab Therapeutics has raised $89 million in Series D funding to support clinical trials for its fibrotic disease treatments, including AGMB-129.
AGMB-129, an oral small molecule inhibitor of ALK5 (搜索) (TGFβ1R (搜索)), is currently in a Phase IIa trial (STENOVA) for fibrostenosing Crohn’s disease (搜索), with interim results expected in early 2025.
The funding will also support the development of AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (搜索) (IPF), and AGMB-101, a liver cirrhosis (搜索) candidate.
Agomab Therapeutics has announced the successful completion of an $89 million Series D funding round, which will be used to advance the clinical development of its pipeline of fibrotic disease treatments. The financing will primarily support the Phase IIa STENOVA trial of AGMB-129, an oral small molecule inhibitor targeting ALK5 (搜索) (TGFβ1R (搜索)) for fibrostenosing Crohn’s disease (搜索) (FSCD). Sanofi and Invus joined the round as new investors.
Advancing AGMB-129 for Fibrostenosing Crohn’s Disease
AGMB-129 is currently being evaluated in the Phase IIa STENOVA trial (NCT05843578), a 90-patient study. The company anticipates sharing interim results from this trial in early 2025. FSCD is characterized by intestinal strictures caused by inflammation and scarring, and there is currently no cure for the condition. Positive data from a Phase I trial (NCT04933565) of AGMB-129, reported in February 2023, demonstrated high local exposure in the ileum, with no drug-related safety signals or dose-limiting toxicities.
Expanding Pipeline: IPF and Liver Cirrhosis
In addition to AGMB-129, the funding will support the development of AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (搜索) (IPF), which is currently in a Phase I trial (NCT06181370). Agomab also plans to initiate clinical development of AGMB-101, a candidate for liver cirrhosis (搜索), which is in the final stages of IND-enabling studies.
Sanofi's Continued Investment in Immunology
Sanofi's investment in Agomab is part of a broader strategy to expand its presence in the immunology space. Recently, Sanofi has engaged in multiple deals, including partnerships with Recludix, Teva Pharmaceutical, and IGM Biosciences. In June 2024, Sanofi entered a $700 million strategic partnership with Belharra Therapeutics to develop small molecule therapies for immunological diseases.
Leadership Perspective
"We are thrilled to have Sanofi and Invus joining our investor syndicate," said Tim Knotnerus, CEO of Agomab. "Their investment as well as the continued support from our existing shareholders is another validation of the trailblazing work our team is conducting in the fields of fibrostenosing Crohn’s disease (搜索) and idiopathic pulmonary fibrosis (搜索)."